Galapagos NV (Euronext & NASDAQ: GLPG) is pleased to announce the appointment of Dr. Paul Stoffels as Chief Executive Officer (CEO), effective April 1, 2022. Dr. Stoffels brings an impressive track record of success in innovative drug discovery and development, and a wealth of experience in biotech and pharma, across a range of roles and therapeutic areas.
Previously, Paul was Vice Chairman of the Executive Committee and Chief Scientific Officer of J&J, where he spearheaded the Company’s research and product pipeline to set the company wide innovation agenda, discovering and developing transformational healthcare solutions, including the recent development of a single-shot COVID-19 vaccine within a record time frame. Prior to that, he was worldwide Chairman Pharmaceuticals of J&J, which under his leadership significantly rejuvenated its product pipeline and adopted a transformational R&D operating model, resulting in the launch of 25 innovative medicines across the globe. He joined J&J in 2002, with the acquisition of Virco and Tibotec, where he was CEO and Chairman respectively, and led the development of several breakthrough products for the treatment of HIV. Galapagos was founded in 1999 as a joint venture between Crucell and Tibotec, and Paul was member of the board of directors of Galapagos from its foundation until 2002.
Dr. Paul Stoffels commented: “I was closely involved in the foundation of Galapagos by Crucell and Tibotec in 1999 and have been following the company as it matured into the fully-fledged biopharma that it is today. I am attracted by the entrepreneurial culture and unwavering commitment to innovation at Galapagos, its strong R&D capabilities, and growing commercial footprint. Underpinned by strong financial resources and supported by the long-term collaboration with Gilead, I am convinced of Galapagos’ unique potential, and I am very excited and honored to be appointed as CEO. I want to express my respect and appreciation to Onno, who successfully built Galapagos from a start-up to an independent, established publicly listed company. I am committed to staying true to the company’s mission of bringing novel modes of action medicines to patients in need of new treatment options.”
Paul studied Medicine at the University of Diepenbeek and the University of Antwerp in Belgium and Infectious Diseases and Tropical Medicine at the Institute of Tropical Medicine in Antwerp, Belgium.
After a transition period during which Onno van de Stolpe will hand over his activities, Paul Stoffels will fully take over as CEO effective April 1, 2022.
Galapagos NV discovers, develops, and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. More information at www.glpg.com